Beta-Blocker Use Across Indian Cardiovascular Practice: Top Takeaways from ROBUST Study
Written By : Anshika Mishra
Published On 2026-03-31 07:00 GMT | Update On 2026-03-31 10:03 GMT
The ROBUST study, one of India's largest cardiovascular KAP (Knowledge, Attitude, and Practice) studies, provides valuable real-world insights into beta-blocker use across the cardiology care continuum.
Conducted among 1,000 healthcare professionals, including consulting physicians, cardiologists, and other specialists, the study assessed prescribing patterns in hypertension, heart failure, post-myocardial infarction (post-MI), chronic coronary syndrome, and atrial fibrillation. The findings were published in the February 2026 issue of JAPI.
A key highlight is the consistent preference for metoprolol, which emerged as the most widely used beta-blocker across all major indications. Beta-blockers were commonly prescribed in hypertensive patients, especially those with elevated heart rate and higher cardiovascular risk. In heart failure and post-MI care, they were recognized as essential therapies, with significant use at discharge to improve outcomes.
Metoprolol also demonstrated meaningful blood pressure reductions in routine practice, reinforcing its clinical effectiveness. Overall, the ROBUST study offers important India-specific evidence, helping bridge the gap between clinical guidelines and real-world practice while supporting optimized cardiovascular care.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.